Galapagos snags co-promotion rights on filgotinib — just before Gilead’s lock-up pact expires
Exactly two years after Gilead $GILD stepped in with $725 million in cash to buy into licensing rights for Galapagos’ $GLPG spotlight drug filgotinib, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
